I have previously discussed a Lyme disease vaccine candidate from Pfizer and Valneva that is starting a phase 3 clinical trial. However, the companies are keeping us updated with their phase 2 results, and there has been exciting news — the pediatric trial (in 5-17-year-olds) showed strong immunogenicity for the new Pfizer-Valneva vaccine.
Of course, dogs have had access to a Lyme disease vaccine, but there has not been a vaccine available for humans for over 20 years. It’s not that dogs are more important than humans (though many of us might argue that point), but about 20 years ago, the anti-vaxxers got the vaccine pulled from the market, one of their few “successes” in getting rid of useful vaccines.
But a small company, Valneva, in partnership with Pfizer, has developed a new vaccine that will be entering Phase 3 clinical trials real soon. Hopefully, we’ll have it in just a few more years.
Let’s first take a look at this disease, and then we will review the vaccine itself along with new results.Read More »Pfizer-Valneva Lyme disease vaccine — phase 2 pediatric trials results